SG11202009564TA - Oxazole compound crystal - Google Patents

Oxazole compound crystal

Info

Publication number
SG11202009564TA
SG11202009564TA SG11202009564TA SG11202009564TA SG11202009564TA SG 11202009564T A SG11202009564T A SG 11202009564TA SG 11202009564T A SG11202009564T A SG 11202009564TA SG 11202009564T A SG11202009564T A SG 11202009564TA SG 11202009564T A SG11202009564T A SG 11202009564TA
Authority
SG
Singapore
Prior art keywords
compound crystal
oxazole compound
oxazole
crystal
compound
Prior art date
Application number
SG11202009564TA
Other languages
English (en)
Inventor
Naohiko Kanai
Takayuki Yasutomi
Ryosuke Hirota
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG11202009564TA publication Critical patent/SG11202009564TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202009564TA 2018-04-04 2019-04-03 Oxazole compound crystal SG11202009564TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072717 2018-04-04
PCT/JP2019/014730 WO2019194211A1 (en) 2018-04-04 2019-04-03 Oxazole compound crystal

Publications (1)

Publication Number Publication Date
SG11202009564TA true SG11202009564TA (en) 2020-10-29

Family

ID=66223774

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009564TA SG11202009564TA (en) 2018-04-04 2019-04-03 Oxazole compound crystal

Country Status (26)

Country Link
US (4) US11414391B2 (enExample)
EP (2) EP3774745B1 (enExample)
JP (4) JP7326295B2 (enExample)
KR (2) KR20250022254A (enExample)
CN (1) CN111902402A (enExample)
AU (2) AU2019249562B2 (enExample)
BR (1) BR112020019377A2 (enExample)
CA (1) CA3095866A1 (enExample)
DK (1) DK3774745T3 (enExample)
EA (1) EA202092393A1 (enExample)
ES (1) ES2982586T3 (enExample)
FI (1) FI3774745T3 (enExample)
HR (1) HRP20240858T1 (enExample)
HU (1) HUE066793T2 (enExample)
IL (2) IL315425A (enExample)
LT (1) LT3774745T (enExample)
MX (1) MX2020010435A (enExample)
MY (1) MY202406A (enExample)
PH (1) PH12020551605A1 (enExample)
PL (1) PL3774745T3 (enExample)
PT (1) PT3774745T (enExample)
SG (1) SG11202009564TA (enExample)
SI (1) SI3774745T1 (enExample)
TW (2) TW202515853A (enExample)
WO (1) WO2019194211A1 (enExample)
ZA (1) ZA202006134B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515853A (zh) * 2018-04-04 2025-04-16 日商大塚製藥股份有限公司 㗁唑化合物晶體
CN118843463A (zh) 2022-03-25 2024-10-25 大塚制药株式会社 创伤治疗用组合物
CN115887463A (zh) * 2022-12-27 2023-04-04 瑞石生物医药有限公司 一种含环酰胺化合物的药物组合物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46792E1 (en) 2005-11-15 2018-04-17 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
EP2890686B1 (en) * 2012-08-30 2017-01-04 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
TW202515853A (zh) * 2018-04-04 2025-04-16 日商大塚製藥股份有限公司 㗁唑化合物晶體

Also Published As

Publication number Publication date
TWI860993B (zh) 2024-11-11
BR112020019377A2 (pt) 2021-01-05
EA202092393A1 (ru) 2021-01-25
IL315425A (en) 2024-11-01
AU2019249562B2 (en) 2024-06-27
ZA202006134B (en) 2023-03-29
EP3774745A1 (en) 2021-02-17
IL277730B2 (en) 2025-02-01
PL3774745T3 (pl) 2024-08-19
HRP20240858T1 (hr) 2024-10-11
JP7326295B2 (ja) 2023-08-15
JP2024001115A (ja) 2024-01-09
HUE066793T2 (hu) 2024-09-28
IL277730A (en) 2020-11-30
KR102764726B1 (ko) 2025-02-11
DK3774745T3 (da) 2024-06-17
EP4400167A3 (en) 2024-09-25
JP2021517111A (ja) 2021-07-15
TW202012380A (zh) 2020-04-01
KR20250022254A (ko) 2025-02-14
JP2025128238A (ja) 2025-09-02
KR20200139736A (ko) 2020-12-14
JP2022037040A (ja) 2022-03-08
US20210147370A1 (en) 2021-05-20
IL277730B1 (en) 2024-10-01
SI3774745T1 (sl) 2024-08-30
AU2019249562A1 (en) 2020-10-22
CN111902402A (zh) 2020-11-06
WO2019194211A1 (en) 2019-10-10
FI3774745T3 (fi) 2024-06-19
EP3774745B1 (en) 2024-05-29
LT3774745T (lt) 2024-07-10
US20250250243A1 (en) 2025-08-07
EP4400167A2 (en) 2024-07-17
AU2024220015A1 (en) 2024-10-17
US11840512B2 (en) 2023-12-12
CA3095866A1 (en) 2019-10-10
PT3774745T (pt) 2024-06-25
US20240076275A1 (en) 2024-03-07
MY202406A (en) 2024-04-27
PH12020551605A1 (en) 2021-04-26
MX2020010435A (es) 2020-10-28
US11414391B2 (en) 2022-08-16
US20220411386A1 (en) 2022-12-29
ES2982586T3 (es) 2024-10-16
TW202515853A (zh) 2025-04-16

Similar Documents

Publication Publication Date Title
IL279468A (en) Crystallographic modifications of odeviccibat
EP3793551A4 (en) OXADIAZOLE COMPOUNDS
SG11202101480XA (en) Novel sulfonamideurea compounds
GB201806578D0 (en) Novel compound
GB201803393D0 (en) Novel compounds
SG11202012765PA (en) Novel compounds
GB201803394D0 (en) Novel compounds
PL3827042T3 (pl) Związek wielo-azyrydynowy
ZA202006134B (en) Oxazole compound crystal
ZA202101671B (en) Imidazopyridinone compound
GB201813060D0 (en) Novel compounds
IL285219A (en) A crystal of the compound diarylthiohydantoin
ZA202100484B (en) Crystal of benzoxazole derivative
GB201813284D0 (en) Novel compounds
GB201813049D0 (en) Novel Compounds
GB201803391D0 (en) Novel compounds
GB201803411D0 (en) Novel compounds
GB201803417D0 (en) Novel compounds
GB201803415D0 (en) Novel compounds
GB201803414D0 (en) Novel compounds
GB201803413D0 (en) Novel compounds
GB201803412D0 (en) Novel compounds
GB201803392D0 (en) Novel compounds
GB201803042D0 (en) Novel Compounds
GB201802117D0 (en) Novel compounds